CNX-774 is a potent Btk inhibitor (IC50 < 1 nM). Recently Bruton's tyrosine kinase (BTK) , a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.
臺(tái)州市科瑞生物技術(shù)有限公司
聯(lián)系商家時(shí)請(qǐng)?zhí)峒癱hemicalbook,有助于交易順利完成!
crene